Hypertrophic cardiomyopathy: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SGLT2 2
• GLP-1 0
• MEK 2
• MAPK 0
• PI3K 0
• STAT3 0
• TTR 0
• AKT 0
• CTNNB1 0
• ERK 0
• IL-6 0
• KRAS 0
• mTOR 0
• NRF2 0
• PSEN1 0
• SHP2 0
• TP53 0

24 of 836 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NHLBI · U24

  2/2 Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy

  New England Research Institutes, Inc.· Wilmington, United States· US$806,069 awarded in fiscal year 2026· until Aug 2032

• NIH NHLBI · UG3

  1/2 Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy

  Icahn School of Medicine at Mount Sinai· New York, United States· US$946,567 awarded in fiscal year 2026· until Aug 2027

• NIH NHLBI · R01

  Discovery of modifier genes and molecular mechanisms in arrhythmogenic cardiomyopathy

  University of Tennessee Health Sci Ctr· Memphis, United States· US$769,447 awarded in fiscal year 2026· until May 2030

• NIH NHLBI · R01

  Mutation-specific responses to myosin inhibitors in human iPSC models of HCM

  University of Wisconsin-Madison· Madison, United States· US$581,307 awarded in fiscal year 2026· until May 2030

• NIH NHLBI · K99

  Investigating the interplay between viscoelastic and growth factor sequestering cues in iPSC-CMs

  University of California Santa Barbara· Santa Barbara, United States· US$130,955 awarded in fiscal year 2026· until Jul 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Bioinspired Modulation of Cardiac Troponin I Splicing to Treat Diastolic Dysfunction (TROPOSplice)

  Centro Nacional de Investigaciones Cardiovasculares Carlos Iii (F.s.p.)· Madrid, Spain· EU contribution €1,499,625· until Jan 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Pushing boundaries: Innovating ultrafast ultrasound imaging to explore genotype-phenotype interplay in young hypertrophic cardiomyopathy – Real-time diagnosis and personalized management (5D ULTRAFAST-HCM)

  Chu Hopitaux de Bordeaux· Talence, France· EU contribution €1,499,425· until Dec 2030

• European Commission (Horizon Europe) · HORIZON-ERC

  Boosting predictive concepts on arrhythmogenesis resolving and unifying cardiac electrophysiology and structural remodelling at organ-level (HeartCORE)

  Consiglio Nazionale Delle Ricerche· Roma, Italy· EU contribution €2,646,938· until Aug 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  INnovative risk Stratification of heart faIlure throuGH explainable machine learning and compuTational modeling of Left Ventricle (INSIGHT-LV)

  Politecnico di Milano· Milano, Italy· EU contribution €193,643· until May 2027

• European Commission (Horizon Europe) · HORIZON-RIA

  Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions (SMASH-HCM)

  Tampereen Korkeakoulusaatio Sr· Tampere, Finland· EU contribution €8,546,366· until Dec 2027· 9 countries

10 of 125 running projects, newest first. Listed amounts together: US$69.9m + €14.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  VIZ ACCESS HCM - Multi-Site Registry

  NCT07103057· Viz.ai, Inc.· Updated 23 Sept 2026

  “Sponsor company opted to shift design into single center investigator initiated study focus.”Registry text, quoted unchanged. Source

• Terminated

  A Cardiac Disease Quality of Life Study

  NCT04080492· The Cleveland Clinic· Updated 17 Sept 2026

  “Enrollment goal not met”Registry text, quoted unchanged. Source

• Terminated

  ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access

  NCT07155434· UltraSight· Updated 9 Mar 2026

  “The sponsor terminated the study following an internal review of program priorities.”Registry text, quoted unchanged. Source

• Terminated

  Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

  NCT06775886· Montefiore Medical Center· Updated 11 Feb 2026

  “PI left the institution. IRB study closure date of 11/12/2025. IRB approved closeout on 2/6/2026.”Registry text, quoted unchanged. Source

• Terminated

  NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study

  NCT06269640· National Heart, Lung, and Blood Institute (NHLBI)· Updated 18 Dec 2025

  “Clinical trials terminated early due to trial feasibility”Registry text, quoted unchanged. Source

• Withdrawn

  OPIE in the Thin Interventricular Septum

  NCT04050579· NYU Langone Health· Updated 11 Jun 2025

  “Study was determined to be focused on Quality Assurance (QA) and Quality Improvement (QI), rather than research, based on its primary purpose and activities. Study was closed prior to enrollment.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Individualized Exercise Training in Hypertrophic Cardiomyopathy

  NCT07835854· Oregon Health and Science University· Source

• A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

  NCT06112743· Bristol-Myers Squibb· Source

• Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients Using Hybrid Digital Twin Solutions

  NCT07131371· Tampere University· Source

• Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Cytokinetics· Source

• A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

  NCT07004972· Bristol-Myers Squibb· Source

• Perfusion Abnormalities in Hypertrophic Cardiomyopathy

  NCT06599229· University of Virginia· Source

• A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

  NCT03723655· Bristol-Myers Squibb· Source

• A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

  NCT06253221· Bristol-Myers Squibb· Source

• NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study

  NCT06269640· National Heart, Lung, and Blood Institute (NHLBI)· Source

• Transapical Beating-Heart Septal Myectomy for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

  NCT05648825· Xiang Wei· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 1
• Mendelian Randomization Analysis 8
• CRISPR-Cas Systems 2
• Gene Expression Profiling 17
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 8
• Proteomics 6
• Metabolomics 2
• Immunohistochemistry 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 39
• Machine Learning 14
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 9

• Effects of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipidemic rats after myocardial infarction.

  J Mol Cell Cardiol, Dec 2003

See which targets of this disease your abstract mentions, and go to the people working on them.